Skip to main content

Table 1 Gedatolisib partially reversed ABCB1-medaited MDR

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Drug IC50 ± SD(RF)
SW620 (μM) SW620/ADR (μΜ)
Doxorubicin 0.042 ± 0.009 (1.00) 10.653 ± 0.600 (253.64)
+ Gedatolisib (0.1 μM) 0.043 ± 0.009 (1.024) 9.767 ± 0.424 (232.55)
+ Gedatolisib (0.2 μM) 0.039 ± 0.010 (0.928) 6.431 ± 0.041 (153.12)*
+ Verapamil (1 μM) 0.038 ± 0.007 (0.905) 0.412 ± 0.030 (9.80)*
Paclitaxel 0.038 ± 0.005 (1.00) 5.422 ± 0.556 (142.68)
+ Gedatolisib (0.1 μM) 0.040 ± 0.004 (1.05) 4.379 ± 0.234 (115.24)*
+ Gedatolisib (0.2 μM) 0.037 ± 0.006 (0.97) 3.273 ± 0.121 (86.13)*
+ Verapamil (1 μM) 0.042 ± 0.004 (1.10) 0.090 ± 0.082 (2.37)*
Vincristine 0.098 ± 0.009 (1.00) 12.472 ± 1.263 (127.27)
+ Gedatolisib (0.1 μM) 0.088 ± 0.008 (0.90) 10.863 ± 1.463 (110.85)*
+ Gedatolisib (0.2 μM) 0.091 ± 0.009 (0.93) 5.324 ± 0.561 (54.33)*
+ Verapamil (1 μM) 0.087 ± 0.009 (0.89) 0.231 ± 0.042 (2.36)*
Cisplatin 3.234 ± 0.194 (1.00) 3.536 ± 0.211 (1.09)
+ Gedatolisib (0.1 μM) 3.354 ± 0.213 (1.04) 3.743 ± 0.263 (1.13)
+ Gedatolisib (0.2 μM) 3.453 ± 0.253 (1.07) 3.243 ± 0.373 (0.8)
+ Verapamil (1 μM) 3.244 ± 0.210 (1.00) 3.543 ± 0.262 (1.07)
  1. Resistance fold (RF) was calculated from dividing the IC50 values of SW620/ADR cells by the IC50 values of SW620 cells in the presence or absence of gedatolisib or verapamil
  2. *Presents when p value is < 0.05. Data was showed with mean ± SD, which is representative for at least three independent experiments